Article Details

Synthetic biology outfit Zymergen sees fledgling stock tumble amid CEO departure, product delays

Retrieved on: 2021-08-04 14:37:30

Tags for this article:

Click the tags to see associated articles and topics

Synthetic biology outfit Zymergen sees fledgling stock tumble amid CEO departure, product delays. View article details on hiswai:

Excerpt

Zymergen said it had about $588 million in remaining cash and equivalents and plans to cut expenses in light of the forecasted drought in revenue ...

Article found on: www.fiercebiotech.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up